European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby ...
Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction ...
GlobalData on MSN15h
Tectonic Therapeutic reports findings from Phase Ia trial of TX45The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.
An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions ...
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...
Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback